ToolAssay

Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy

Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.

Asked 1.4x its listed price for its own exampleour last check, 2026-09-28
1 of 1checks answered this week
305 msmedian answer time
$0.005listed price per call
$0.007price it asked us

Paid test badge: not yet. The checks above are free: we call the tool without paying and read the payment request it sends back. The Verified badge needs paid calls whose answers match the promised output, and nobody can buy a badge.

Endpoint

POST https://api.magentlab.com/api/calc/prevail

CategoryEverything else
Provider hostapi.magentlab.com
Networkseip155:8453
Payment schemesexact
Self-reported calls, 30 days0 from 0 payers (the provider's figure, not ours)

Our checks, last 30 days

DayResultHTTPAskedTime
2026-09-28 valid payment request 402$0.007 305 ms

Example input (from the provider)

{
  "body": {
    "items": [
      {
        "albumin_g_dl": 4,
        "alp_below_uln": true,
        "bone_mets_lt_10": true,
        "hemoglobin_g_dl": 13,
        "ldh_below_uln": true,
        "months_since_diagnosis": 60,
        "nlr_lt_2_5": true,
        "no_liver_metastases": true,
        "pain_0_to_1": true,
        "psa_ng_ml": 20,
        "treatment_enzalutamide": true
      },
      {
        "albumin_g_dl": 4,
        "alp_below_uln": true,
        "bone_mets_lt_10": true,
        "hemoglobin_g_dl": 13,
        "ldh_below_uln": true,
        "months_since_diagnosis": 60,
        "nlr_lt_2_5": true,
        "no_liver_metastases": true,
        "pain_0_to_1": true,
        "psa_ng_ml": 20,
        "treatment_enzalutamide": true
      }
    ]
  },
  "method": "POST",
  "type": "http"
}

Promised output schema (from the provider)

{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "properties": {
    "input": {
      "additionalProperties": false,
      "properties": {
        "body": {
          "additionalProperties": false,
          "properties": {
            "items": {
              "items": {
                "properties": {
                  "albumin_g_dl": {
                    "description": "Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin.",
                    "type": "number"
                  },
                  "alp_below_uln": {
                    "description": "Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus \u2265ULN) has HR 0.79. magent does not assay ALP or apply ULN.",
                    "type": "boolean"
                  },
                  "bone_mets_lt_10": {
                    "description": "Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus \u226510) has HR 0.68. magent does not read bone scans.",
                    "type": "boolean"
                  },
                  "hemoglobin_g_dl": {
                    "description": "Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin.",
                    "type": "number"
                  },
                  "ldh_below_uln": {
                    "description": "Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus \u22651\u00d7ULN) has HR 0.67. magent does not assay LDH or apply ULN.",
                    "type": "boolean"
                  },
                  "months_since_diagnosis": {
                    "description": "Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval.",
                    "type": "number"
                  },
                  "nlr_lt_2_5": {
                    "description": "Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus \u22652.5) has HR 0.69. magent does not compute NLR from counts.",
                    "type": "boolean"
                  },
                  "no_liver_metastases": {
                    "description": "No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging.",
                    "type": "boolean"
                  },
                  "pain_0_to_1": {
                    "description": "Pain score 0-1 versus \u22652 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus \u22652) has HR 0.77. magent does not assign pain scores.",
                    "type": "boolean"
                  },
                  "psa_ng_ml": {
                    "description": "Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA.",
                    "type": "number"
                  },
                  "treatment_enzalutamide": {
                    "description": "true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order.",
                    "type": "boolean"
                  }
                },
                "required": [
                  "albumin_g_dl",
                  "alp_below_uln",
                  "bone_mets_lt_10",
                  "hemoglobin_g_dl",
                  "ldh_below_uln",
                  "nlr_lt_2_5",
                  "pain_0_to_1",
                  "no_liver_metastases",
                  "psa_ng_ml",
                  "months_since_diagnosis",
                  "treatment_enzalutamide"
                ],
                "type": "object"
              },
              "maxItems": 25,
              "minItems": 1,
              "type": "array"
            }
          },
          "required": [
            "items"
          ],
          "type": "object"
        },
        "headers": {
          "additionalProperties": {
            "type": "string"
          },
          "type": "object"
        },
        "method": {
          "const": "POST",
          "type": "string"
        },
        "type": {
          "const": "http",
          "type": "string"
        }
      },
      "required": [
        "type",
        "method"
      ],
      "type": "object"
    },
    "output": {
      "properties": {
        "example": {
          "type": "object"
        },
        "type": {
          "type": "string"
        }
      },
      "required": [
        "type"
      ],
      "type": "object"
    }
  },
  "required": [
    "input"
  ],
  "type": "object"
}

This page as JSON